Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial.

Kevin W GareyJacob McPhersonAn Q DinhChenlin HuJinhee JoWeiqun WangChris K LancasterAnne J Gonzales-LunaCaroline LoveallKhurshida BegumM Jahangir AlamMichael H SilvermanBlake M Hanson

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

In this phase 2a study, 10 of 10 patients achieved SCC, demonstrated favorable pharmacokinetics, minimal AEs, and beneficial microbiome and bile acids results. These results support continued clinical development.

Keyphrases

clinical trial
clostridium difficile
double blind
phase ii
study protocol
cross sectional
randomized controlled trial